Vardenafil (Levitra/Staxyn) vs Alprostadil (Caverject/MUSE) in Special Populations: Head-to-Head

What Is Each Drug and How Does It Work?

Vardenafil blocks phosphodiesterase type 5, which raises cyclic GMP levels inside penile smooth muscle and allows an erection only when sexual stimulation is present. Alprostadil is synthetic prostaglandin E1 that directly activates adenylate cyclase in smooth muscle cells, producing erection independent of sexual arousal. That mechanistic difference explains most of the clinical trade-offs discussed below.

Vardenafil: Oral PDE5 Inhibition

Levitra (conventional film-coated tablet) and Staxyn (orodispersible tablet, ODT) both deliver vardenafil at a standard 10 mg starting dose. Levitra is dose-adjustable from 5 mg to 20 mg; Staxyn is fixed at 10 mg and should not be split. The FDA approved vardenafil in August 2003, and the label is available at accessdata.fda.gov [1]. Peak plasma levels arrive in roughly 45 minutes; a high-fat meal delays but does not abolish absorption for Levitra (though Staxyn absorption is reduced roughly 25% with a high-fat meal).

Alprostadil: Local Prostaglandin E1 Delivery

Caverject (intracavernosal injection, ICi) and MUSE (medicated urethral system for erection, intraurethral suppository) both contain alprostadil but differ sharply in bioavailability. Caverject delivers drug directly into the corpus cavernosum at 2.5 to 40 mcg per dose; MUSE delivers 125 to 1,000 mcg into the urethra, of which only a fraction reaches erectile tissue. Onset with Caverject is 5 to 20 minutes regardless of sexual stimulation [2]. The FDA label for Caverject Impulse is at accessdata.fda.gov [2].

Special Population 1: Diabetes-Associated ED

Diabetic men show blunted response to PDE5 inhibitors because endothelial nitric oxide synthesis is impaired by glycation, oxidative stress, and autonomic neuropathy. Both drugs have been tested specifically in this group.

Vardenafil in Diabetic ED

The Porst et al. Multicenter trial (N=452, published 2003) enrolled men with type 1 and type 2 diabetes and randomized them to vardenafil 10 mg, 20 mg, or placebo. At 20 mg, 57% of attempts resulted in successful intercourse versus 23% for placebo (P<0.001) [3]. The International Index of Erectile Function (IIEF) erectile function domain score improved by 6.6 points from baseline with 20 mg vardenafil versus 1.4 points with placebo [3]. Glycemic control did not significantly affect response, though men with HbA1c above 10% were excluded.

Alprostadil in Diabetic ED

Intracavernosal alprostadil produces erections sufficient for intercourse in approximately 60 to 65% of diabetic men, according to pooled data from the Caverject key trials [4]. Peripheral neuropathy, which blunts penile pain sensation, may paradoxically reduce the chief side effect of injection therapy, making Caverject more tolerable in diabetic patients than in the general ED population. For men whose PDE5 response is partial, combination therapy (low-dose vardenafil plus low-dose alprostadil ICi) is an off-label strategy supported by case series, though it carries additive hypotensive risk.

Clinical Verdict for Diabetes

Vardenafil 20 mg is a reasonable first-line choice given its oral route and documented 57% intercourse success rate in the Porst trial [3]. Alprostadil ICi is the preferred second-line option when vardenafil fails or produces inadequate rigidity, particularly in type 1 diabetic men with severe autonomic neuropathy.

Special Population 2: Post-Radical Prostatectomy ED

Nerve-sparing status is the single strongest predictor of which agent will work after radical prostatectomy. Both cavernous nerves must be intact for PDE5 inhibitors to achieve full effect, because the mechanism requires neurally released nitric oxide.

Vardenafil Post-Prostatectomy

A randomized, double-blind trial by Brock et al. (Urology 2003, N=440) tested vardenafil 10 mg and 20 mg after bilateral nerve-sparing radical prostatectomy. The 20 mg dose achieved successful intercourse in 65% of attempts for bilateral nerve-sparing patients versus 12% for placebo, a number that dropped to roughly 30% in unilateral nerve-sparing men [5]. In non-nerve-sparing surgery, response to vardenafil is minimal because the required nitric oxide signal is absent.

Alprostadil Post-Prostatectomy

Alprostadil bypasses the damaged nerve pathway entirely. The landmark Linet and Ogrinc NEJM 1996 trial (N=296) established intracavernosal alprostadil as effective in a mixed ED population, with 94% of home injections producing erections [6]. Post-prostatectomy subgroup analyses from Caverject registration data show erection rates of approximately 70 to 80% regardless of nerve-sparing status, because the drug acts directly on smooth muscle receptors rather than requiring neural input [4].

Clinical Verdict Post-Prostatectomy

For bilateral nerve-sparing surgery, vardenafil 20 mg is a rational first choice. For non-nerve-sparing or unilateral nerve-sparing cases, alprostadil ICi should be offered early, both for acute erectile function and because penile rehabilitation data suggest that regular oxygenation of cavernous tissue reduces fibrosis risk. The AUA 2018 ED Guideline states: "The evidence-based standard for penile rehabilitation remains unclear, but intracavernosal injection therapy is frequently used" [7].

Special Population 3: Cardiovascular Disease and Hypertension

Choosing an ED agent in men with established cardiovascular disease requires assessing nitrate use, blood pressure status, and exercise tolerance.

Vardenafil and Cardiovascular Considerations

Vardenafil carries an absolute contraindication with all organic nitrates and nitric oxide donors due to the risk of severe hypotension [1]. The drug also prolongs the QTc interval at supratherapeutic doses; the FDA label warns against use with class IA antiarrhythmics (quinidine, procainamide) and class III agents (amiodarone, sotalol) [1]. Men with stable coronary artery disease who are not on nitrates and can achieve 3 to 4 METs of exertion without angina can generally take vardenafil safely, per the Princeton III Consensus Panel [8].

Alprostadil and Cardiovascular Considerations

Alprostadil does not interact with nitrates. Men on long-acting nitrates who cannot tolerate a nitrate holiday are candidates for alprostadil ICi. Systemic hypotension is possible but less pronounced than with PDE5 inhibitors, because drug absorption from the corpus cavernosum into systemic circulation is limited. MUSE carries a modestly higher systemic absorption rate than Caverject and may cause symptomatic hypotension in up to 3% of users [2].

Hypertension-Specific Data

In men with hypertension on antihypertensives, vardenafil 20 mg produced additive blood pressure lowering of approximately 5 to 8 mmHg systolic in pharmacodynamic studies included in the FDA label [1]. Dose reduction to 5 mg is recommended for men on alpha-blockers (except tamsulosin 0.4 mg, for which a specific interaction study showed acceptable hemodynamics).

Clinical Verdict for Cardiovascular Disease

Men on nitrates: alprostadil is the only viable option from this pair. Men not on nitrates with stable CAD: vardenafil is first-line after risk stratification using the Princeton III framework. Men with severe aortic stenosis or uncontrolled hypertension (>170/100 mmHg) should defer ED therapy until cardiovascular status is stabilized.

Special Population 4: Spinal Cord Injury

Spinal cord injury (SCI) disrupts both psychogenic and reflex erection pathways to varying degrees, depending on lesion level and completeness.

Vardenafil in SCI

A double-blind crossover study by Giuliano et al. (Eur Urol 2002, N=41) found that vardenafil 20 mg significantly improved IIEF erectile function domain scores (mean increase 10.0 vs. 1.7 for placebo, P<0.001) in men with SCI [9]. Reflex erections (sacral reflex arc S2, S4 intact) responded better than psychogenic pathways, consistent with the PDE5 inhibitor mechanism requiring some intact neural signaling.

Alprostadil in SCI

Alprostadil ICi is effective in SCI regardless of lesion completeness, because it acts peripherally. Small case series report erection success rates of 80 to 90% in SCI men using Caverject, with penile pain reduced by the sensory deficits common in this population [10]. Autonomic dysreflexia is a concern in lesions above T6 and requires that each man's blood pressure be monitored during the first injection attempt.

Clinical Verdict for SCI

For incomplete SCI with preserved sacral reflexes, vardenafil is a non-invasive first option. For complete SCI or when vardenafil fails, alprostadil ICi is highly effective and uniquely well tolerated (pain is the primary side effect, and SCI patients often have reduced penile sensation). Autonomic dysreflexia monitoring is mandatory above T6.

Head-to-Head Efficacy Summary

The table below organizes response rates by population, drawing from the clinical trial data cited throughout this article.

| Population | Vardenafil Success Rate | Alprostadil Success Rate | Preferred First Agent | |---|---|---|---| | Diabetic ED (type 1/2) | ~57% (Porst 2003, 20 mg) [3] | ~60 to 65% (Caverject pivotals) [4] | Vardenafil (oral); alprostadil if fails | | Post-prostatectomy, bilateral NS | ~65% (Brock 2003) [5] | ~70 to 80% (Caverject subgroup) [4] | Vardenafil; alprostadil if fails | | Post-prostatectomy, non-NS | ~30% or less [5] | ~70 to 80% [4] | Alprostadil ICi | | SCI, incomplete | ~60 to 70% (Giuliano 2002) [9] | ~80 to 90% (case series) [10] | Vardenafil if sacral reflex intact | | SCI, complete | Minimal response | ~80 to 90% [10] | Alprostadil ICi | | CAD on nitrates | Contraindicated [1] | Effective [2] | Alprostadil only | | Stable CAD, no nitrates | Effective after risk stratification [8] | Effective [2] | Vardenafil |

Switching from Vardenafil to Alprostadil: When and How

Switching is appropriate in four clinical scenarios: (1) vardenafil failure defined as inadequate erection on three separate 20 mg attempts with adequate sexual stimulation, (2) development of a nitrate indication making PDE5 inhibitors contraindicated, (3) advancement to non-nerve-sparing prostatectomy, and (4) patient preference for stimulation-independent erections.

Titration Protocol for Alprostadil ICi

Caverject must be titrated in a clinical setting. Begin at 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED. The dose is doubled at each office visit until a full erection lasting no more than 60 minutes is achieved, with no more than two dose increments per visit. The maximum recommended single dose is 40 mcg [2]. Men should be observed for 30 minutes post-injection before leaving the office on the first attempt.

Overlap Period Considerations

No pharmacokinetic washout is required before switching from vardenafil (half-life approximately 4 to 5 hours) to alprostadil. The two can theoretically be combined in a supervised low-dose protocol, though this is off-label. Combined use may cause additive hypotension; the patient should be sitting or supine for 30 minutes after any combination injection.

MUSE vs. Caverject as the Alprostadil Vehicle

MUSE offers needle-free delivery but requires a functioning urethral-to-cavernous blood supply for drug transfer. Efficacy is meaningfully lower: a key MUSE trial showed 43% of at-home intercourse attempts successful versus the ~70 to 80% reported with Caverject ICi [11]. In post-prostatectomy patients specifically, urethral anatomy changes after surgery can impair MUSE absorption further, making Caverject the preferred alprostadil vehicle in that population.

Safety, Tolerability, and Side-Effect Comparison

Both agents are generally safe when prescribed within labeled indications, but their side-effect profiles are almost entirely non-overlapping.

Vardenafil Side Effects

The most common adverse effects reported in registration trials are headache (14 to 21%), flushing (11 to 13%), rhinitis (9 to 10%), and dyspepsia (4 to 6%) [1]. Visual disturbance occurs in less than 2% of users. QTc prolongation is dose-dependent; Staxyn ODT achieves higher peak plasma concentrations than Levitra tablets at the same nominal dose, so the FDA label advises caution with Staxyn in men at risk for QT prolongation [1].

Alprostadil Side Effects

Penile pain after intracavernosal injection occurs in approximately 30 to 35% of patients across registration studies, though severe pain is less common and often diminishes with ongoing use [2]. Prolonged erection (>4 hours, priapism) affects roughly 1% of injections; men must be counseled to seek emergency care if erection persists beyond 4 hours. Penile fibrosis develops in up to 5% of long-term users. MUSE adds urethral burning (burning reported by up to 32% of users) and systemic hypotension in roughly 3% [2].

Dosing Quick Reference

Vardenafil

• Levitra: 5 mg, 10 mg (starting), or 20 mg orally 30 to 60 minutes before sex; once per 24 hours maximum.
• Staxyn: 10 mg ODT dissolved on tongue; not interchangeable mg-for-mg with Levitra due to higher Cmax.
• Renal impairment: no dose adjustment needed.
• Hepatic impairment (Child-Pugh B): maximum 10 mg; avoid in Child-Pugh C.
• Age >65: start at 5 mg.

Alprostadil

• Caverject: start 2.5 to 5 mcg; titrate to 40 mcg maximum; inject into lateral corpus cavernosum; maximum 3 injections per week, no two on consecutive days.
• MUSE: 125 to 1,000 mcg; insert into urethra after urinating; do not use more than twice in 24 hours.
• Renal/hepatic impairment: no specific dose adjustment in label, though caution is warranted with severe impairment.

Cost, Access, and Adherence Factors

Vardenafil generic became available in the United States in 2018, reducing out-of-pocket cost substantially. A 30-tablet supply of generic vardenafil 20 mg costs roughly $60 to 100 at major pharmacy chains with GoodRx discounts as of early 2025. Caverject remains brand-only in the US and may cost $150 to 300 per kit of 6 cartridges; compounded alprostadil ICi (prepared by licensed compounding pharmacies) is considerably less expensive, often $60 to 90 for a 10-dose vial, but is not FDA-approved [2].

Adherence to injection therapy drops over time. A review of ICi programs found that 50 to 60% of men discontinue within 2 years, primarily due to pain and inconvenience [12]. Oral vardenafil has substantially better long-term adherence in the general ED population, a factor that may outweigh modest efficacy differences in men who have partial PDE5 response.